The $37 million debt facility from Avenue Capital Group supplies Citius Oncology with non-dilutive ammunition at a critical juncture. LYMPHIR, a reformulated IL-2–diphtheria toxin fusion protein, earned accelerated approval in August 2024 for relapsed/refractory CTCL — a niche hematologic malignancy with roughly 3,000 new U.S. cases annually. The drug entered a market dominated by mogamulizumab (Kyowa Kirin’s Poteligeo) and brentuximab vedotin (Seagen’s Adcetris), but as the sole IL-2 receptor-directed therapy, it targets CD25-expressing tumors. Launching a new oncology brand against entrenched players requires heavy investment in disease education, pharmacy distribution, and reimbursement infrastructure — exactly the use case Avenue’s debt is designed to fund.
The debt structure keeps our equity story intact while giving us the resources to build a commercial engine for LYMPHIR and expand into PTCL.
Avenue’s Calculus: Credit Over Equity in a Thawing Biotech Market
Avenue Capital Group, known for structuring bespoke debt to growth-stage companies, steps in as public biotech equity raises remain sporadic. Citius Oncology (Nasdaq: CTOR) has seen its stock trade below trailing public offerings, making dilutive financing unattractive. The debt deal includes equity conversion clauses typical of Avenue vehicles, but press materials emphasized the non-dilutive nature upfront. This is a bet that LYMPHIR’s revenue trajectory — still unproven post-launch — can service the debt before conversion becomes relevant. The structure mirrors recent Avenue deals with companies like Scynexis, where product revenue milestones trigger repayment flexibility. For Citius, the deal extends cash runway into 2027 without resetting shareholder expectations.
LYMPHIR’s Niche: CTCL Commercial Reality
CTCL is a fragmented market with academic center hubs, making outreach and patient identification key drivers. LYMPHIR’s place in therapy is late-line, after systemic options like bexarotene or interferon, but before clinical trials. The drug’s real-world adoption will depend on demonstrating tolerability advantages — the original Ontak formulation was plagued by capillary leak syndrome, though the refreshed version claims a better safety profile. Pricing remains undisclosed, but analysts expect a premium to Adcetris’s ~$150,000 annual course, given orphan drug dynamics. Citius must also fund Phase 2 expansion into PTCL, a larger but more competitive market, where LYMPHIR will face off against agents like belinostat and the emergent EZH1/2 inhibitors.
The debt sliver positions Citius Oncology to execute on a near-term catalyst — converting clinical proof into commercial proof — without the overhang of secondary equity offerings. Should LYMPHIR prescriber uptake meet Avenue’s revenue covenants, the company can revisit equity at a higher valuation. If not, the debt load pressures margins. For now, the deal buys time for the first CTCL-specific targeted toxin in a market that hasn’t seen new mechanism innovation since Poteligeo’s 2018 approval.
